tradingkey.logo

NeuroOne Medical Technologies Corp

NMTC
0.734USD
+0.018+2.53%
收盘 12/19, 16:00美东报价延迟15分钟
36.58M总市值
亏损市盈率 TTM

NeuroOne Medical Technologies Corp

0.734
+0.018+2.53%

关于 NeuroOne Medical Technologies Corp 公司

NeuroOne Medical Technologies Corporation is a medical technology company. It is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.

NeuroOne Medical Technologies Corp简介

公司代码NMTC
公司名称NeuroOne Medical Technologies Corp
上市日期Nov 09, 2012
CEORosa (David A)
员工数量17
证券类型Ordinary Share
年结日Nov 09
公司地址7599 Anagram Dr
城市EDEN PRAIRIE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编55344-7399
电话19524261383
网址https://nmtc1.com/
公司代码NMTC
上市日期Nov 09, 2012
CEORosa (David A)

NeuroOne Medical Technologies Corp公司高管

名称
名称/职务
职务
持股
持股变动
Mr. David A. (Dave) Rosa
Mr. David A. (Dave) Rosa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
615.75K
-0.40%
Mr. Mark Christianson
Mr. Mark Christianson
Co-Founder, Business Development Director, Medical Sales Liaison
Co-Founder, Business Development Director, Medical Sales Liaison
230.99K
-11.58%
Mr. Paul Buckman
Mr. Paul Buckman
Independent Chairman of the Board
Independent Chairman of the Board
136.80K
+25.48%
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Independent Director
Independent Director
114.41K
+32.06%
Mr. Steve Mertens
Mr. Steve Mertens
Chief Technology Officer
Chief Technology Officer
101.75K
-0.88%
Mr. Edward (Ed) Andrle
Mr. Edward (Ed) Andrle
Independent Director
Independent Director
92.00K
+43.25%
Mr. Chris Donovan
Mr. Chris Donovan
Investor Relations
Investor Relations
--
--
Ms. Emily Johns
Ms. Emily Johns
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Mr. Ronald (Ron) Mcclurg
Mr. Ronald (Ron) Mcclurg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Christopher R. Volker
Mr. Christopher R. Volker
Chief Operating Officer
Chief Operating Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. David A. (Dave) Rosa
Mr. David A. (Dave) Rosa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
615.75K
-0.40%
Mr. Mark Christianson
Mr. Mark Christianson
Co-Founder, Business Development Director, Medical Sales Liaison
Co-Founder, Business Development Director, Medical Sales Liaison
230.99K
-11.58%
Mr. Paul Buckman
Mr. Paul Buckman
Independent Chairman of the Board
Independent Chairman of the Board
136.80K
+25.48%
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Independent Director
Independent Director
114.41K
+32.06%
Mr. Steve Mertens
Mr. Steve Mertens
Chief Technology Officer
Chief Technology Officer
101.75K
-0.88%
Mr. Edward (Ed) Andrle
Mr. Edward (Ed) Andrle
Independent Director
Independent Director
92.00K
+43.25%

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Merchant Adventure Fund LP
8.33%
Bleichroeder LP
7.93%
Manchester Management Company, L.L.C.
4.69%
Sio Capital Management, LLC
4.68%
Bard Associates Inc.
3.67%
其他
70.69%
持股股东
持股股东
占比
Merchant Adventure Fund LP
8.33%
Bleichroeder LP
7.93%
Manchester Management Company, L.L.C.
4.69%
Sio Capital Management, LLC
4.68%
Bard Associates Inc.
3.67%
其他
70.69%
股东类型
持股股东
占比
Investment Advisor
18.22%
Hedge Fund
11.19%
Corporation
8.33%
Individual Investor
4.14%
Investment Advisor/Hedge Fund
3.26%
Research Firm
0.55%
Venture Capital
0.04%
其他
54.27%

机构持股

更新时间: 10月5日 周日
更新时间: 10月5日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q3
51
17.15M
34.30%
+9.56M
2025Q2
52
13.28M
26.66%
+2.81M
2025Q1
54
11.51M
24.26%
+968.46K
2024Q4
55
12.46M
40.67%
+1.38M
2024Q3
55
11.22M
39.84%
+2.23M
2024Q2
51
10.72M
41.07%
+2.35M
2024Q1
52
11.45M
45.01%
+2.75M
2023Q4
57
9.37M
38.68%
+871.77K
2023Q3
54
7.90M
33.50%
+2.01M
2023Q2
48
4.40M
25.73%
-1.65M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Merchant Adventure Fund LP
4.20M
8.4%
+2.95M
+236.00%
Dec 31, 2024
Bleichroeder LP
4.00M
8%
+4.00M
--
Jun 30, 2025
Manchester Management Company, L.L.C.
2.36M
4.73%
+864.05K
+57.60%
Jan 03, 2025
Sio Capital Management, LLC
3.52M
7.05%
+3.52M
--
Jun 30, 2025
Bard Associates Inc.
1.85M
3.71%
+1.85M
--
Jun 30, 2025
The Vanguard Group, Inc.
1.20M
2.41%
+91.91K
+8.27%
Jun 30, 2025
Perkins Capital Management, Inc.
1.50M
3%
+1.50M
--
Jun 30, 2025
AWM Investment Company, Inc.
916.67K
1.83%
-250.00K
-21.43%
Jun 30, 2025
Renaissance Technologies LLC
468.90K
0.94%
+468.90K
--
Jun 30, 2025
Rosa (David A)
615.75K
1.23%
-2.46K
-0.40%
Sep 30, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

NeuroOne Medical Technologies Corp的前五大股东是谁?

NeuroOne Medical Technologies Corp 的前五大股东如下:
Merchant Adventure Fund LP持有股份:4.20M,占总股份比例:8.40%。
Bleichroeder LP持有股份:4.00M,占总股份比例:8.00%。
Manchester Management Company, L.L.C.持有股份:2.36M,占总股份比例:4.73%。
Sio Capital Management, LLC持有股份:3.52M,占总股份比例:7.05%。
Bard Associates Inc.持有股份:1.85M,占总股份比例:3.71%。

NeuroOne Medical Technologies Corp的前三大股东类型是什么?

NeuroOne Medical Technologies Corp 的前三大股东类型分别是:
Merchant Adventure Fund LP
Bleichroeder LP
Manchester Management Company, L.L.C.

有多少机构持有NeuroOne Medical Technologies Corp(NMTC)的股份?

截至2025Q3,共有51家机构持有NeuroOne Medical Technologies Corp的股份,合计持有的股份价值约为17.15M,占公司总股份的34.30%。与2025Q2相比,机构持股有所增加,增幅为7.64%。

哪个业务部门对NeuroOne Medical Technologies Corp的收入贡献最大?

在--,--业务部门对NeuroOne Medical Technologies Corp的收入贡献最大,创收--,占总收入的--%。
KeyAI